Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer.

Miguel Quintela-FandinoSerafín MoralesAlfonso Cortés-SalgadoLuis MansoJuan V ApalaManuel MuñozAriadna Gasol CudosJoel Salla FortunyMaría GionAntonio Lopez-AlonsoJavier CortesJuan GuerraDiego MalónEduardo CaleirasFrancisca MuleroSilvana Mouron

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

ME-344 has significant biological antitumor activity in HER2-negative breast cancer, particularly after induction of vascular normalization and tissue reoxygenation with bevacizumab.

Keyphrases

phase iii
double blind
phase ii
open label
placebo controlled
clinical trial
metastatic colorectal cancer
study protocol
oxidative stress
young adults